Citations

Clear

4847 citation(s) found for "Tu, Eric".

Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Ramsey, Keri , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine M., Schmechel, Donald E., Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | February 12, 2008 | Volume: 33 | Issue: 2 | Pages: 240-256

10.1152/physiolgenomics.00242.2007 | PMID 18270320 Get It

Alzheimer's Disease (AD) is the most widespread form of dementia during the later stages of life. If improved therapeutics are not developed, the prevalence of AD will drastically increase in the coming years as the world's population ages. By identifying differences in neuronal gene expression profiles between healthy elderly persons and individuals diagnosed with AD, we may be able to better understand the molecular mechanisms that drive AD pathogenesis, including the formation of amyloid plaques and neurofibrillary tangles. In this study, we expression profiled histopathologically normal cortical neurons collected with laser capture microdissection (LCM) from six anatomically and functionally discrete postmortem brain regions in 34 AD-afflicted individuals, using Affymetrix Human Genome U133 Plus 2.0 microarrays. These regions include the entorhinal cortex, hippocampus, middle temporal gyrus, posterior cingulate cortex, superior frontal gyrus, and primary visual cortex. This study is predicated on previous parallel research on the postmortem brains of the same six regions in 14 healthy elderly individuals, for which LCM neurons were similarly processed for expression analysis. We identified significant regional differential expression in AD brains compared with control brains including expression changes of genes previously implicated in AD pathogenesis, particularly with regard to tangle and plaque formation. Pinpointing the expression of factors that may play a role in AD pathogenesis provides a foundation for future identification of new targets for improved AD therapeutics. We provide this carefully phenotyped, laser capture microdissected intraindividual brain region expression data set to the community as a public resource.
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
Smedby, Karin E. , Vajdic, Claire M. , Falster, Michael O. , Martı́nez-Maza, Otoniel , Turner, Jennifer , Hjalgrim, Henrik , Vineis, Paolo , Costantini, Adele Seniori , Bracci, Paige M. , Holly, Elizabeth A., Willett, Eleanor V., Spinelli, John J., Vecchia, Carlo La , Zheng, Tongzhang, Becker, Nikolaus, Sanjosé, Sílvia de , Maso, Luigino Dal , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Brennan, Paul , Severson, Richard K., Cerhan, James R. , Breen, Elizabeth C. , Birmann, Brenda M. , Grulich, Andrew E. , Kane, Eleanor , Engels, Eric A. , Chiu, Brian C.‐H. , Maynadié, Marc , Davis, Scott , Cozen, Wendy , Cerhan, James R , Turner, Jennifer , Cocco, Pierluigi , Vajdic, Claire M , Kane, Eleanor , Martínez-Maza, Otoniel , Birmann, Brenda M

Mayo Clinic

Blood | February 8, 2008 | Volume: 111 | Issue: 8 | Pages: 4029-4038

10.1182/blood-2007-10-119974 | PMID 18263783 Get It

Abstract Some autoimmune disorders are increasingly recognized as risk factors for non-Hodgkin lymphoma (NHL) overall, but large-scale systematic assessments of risk of NHL subtypes are lacking. We performed a pooled analysis of self-reported autoimmune conditions and risk of NHL and subtypes, including 29 423 participants in 12 case-control studies. We computed pooled odds ratios (OR) and 95% confidence intervals (CI) in a joint fixed-effects model. Sjögren syndrome was associated with a 6.5-fold increased risk of NHL, a 1000-fold increased risk of parotid gland marginal zone lymphoma (OR = 996; 95% CI, 216-4596), and with diffuse large B-cell and follicular lymphomas. Systemic lupus erythematosus was associated with a 2.7-fold increased risk of NHL and with diffuse large B-cell and marginal zone lymphomas. Hemolytic anemia was associated with diffuse large B-cell NHL. T-cell NHL risk was increased for patients with celiac disease and psoriasis. Results for rheumatoid arthritis were heterogeneous between studies. Inflammatory bowel disorders, type 1 diabetes, sarcoidosis, pernicious anemia, and multiple sclerosis were not associated with risk of NHL or subtypes. Thus, specific autoimmune disorders are associated with NHL risk beyond the development of rare NHL subtypes in affected organs. The pattern of associations with NHL subtypes may harbor clues to lymphomagenesis.
Genetic and Clinical Heterogeneity in eIF2B-Related Disorder
Maletkovic, Jelena , Gorospe, J. Rafael, Gordon, Erynn S. , Mintz, Michelle, Hoffman, Eric P. , Alper, Gülay, Singhal, Bhim , Amartino, Hernán , Brown, Candida, Chan, Alicia , Renaud, Deborah L. , Geraghty, Michael T. , Jensen, Lloyd, Şenbil, Nesrin , Kadom, Nadja , Nazarian, Javad , Feng, Yuanjian, Wang, Zuyi, Morizono, Hiroki , Vanderver, Adeline , Schiffmann, Raphael , Lynch, David R. , Harding, Cary O. , Hartka, Thomas , Nazarian, Javad

Mayo Clinic

Journal of Child Neurology | February 8, 2008 | Volume: 23 | Issue: 2 | Pages: 205-215

10.1177/0883073807308705 | PMID 18263758 Get It

Eukaryotic initiation factor 2B (eIF2B)-related disorders are heritable white matter disorders with a variable clinical phenotype (including vanishing white matter disease and ovarioleukodystrophy) and an equally heterogeneous genotype. We report 9 novel mutations in the EIF2B genes in our subject population, increasing the number of known mutations to more than 120. Using homology modeling, we have analyzed the impact of novel mutations on the 5 subunits of the eIF2B protein. Although recurrent mutations have been found at CpG dinucleotides in the EIF2B genes, the high incidence of private or low frequency mutations increases the challenge of providing rapid genetic confirmation of this disorder, and limits the application of EIF2B screening in cases of undiagnosed leukodystrophy.
Neuropathology of brain death in the modern transplant era
Pfeifer, Eric A., Wijdicks, Eelco F. M.

Mayo Clinic

Neurology | February 7, 2008 | Volume: 70 | Issue: 15 | Pages: 1234-1237

10.1212/01.wnl.0000289762.50376.b6 | PMID 18256368 Get It

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
Perez, Edith A. , Davidson, Nancy E. , Hudis, Clifford A. , Martino, Silvana, Dakhil, Shaker R. , Jaffe, Allan S. , Rodeheffer, Richard J. , Suman, Vera J. , Sledge, George W. , Kaufman, Peter A. , Gralow, Julie R. , Ingle, James N. , Winer, Eric P. , Gelmon, Karen A. , Gersh, Bernard J. , Jaffe, Allan S.

Mayo Clinic

Journal of Clinical Oncology | February 5, 2008 | Volume: 26 | Issue: 8 | Pages: 1231-1238

10.1200/jco.2007.13.5467 | PMID 18250349 Get It

Purpose To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial. Patients and Methods Patients with HER2-positive operable breast cancer were randomly assigned to doxorubicin plus cyclophosphamide (AC) followed by either weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or paclitaxel plus trastuzumab then trastuzumab alone (arm C). Left ventricular ejection fraction (LVEF) was evaluated at registration and 3, 6, 9, and 18 to 21 months. Results Of 2,992 patients completing AC, 5.0% had LVEF decreases disallowing trastuzumab (decrease below normal: 2.4%, decrease > 15%: 2.6%). There were 1,944 patients with satisfactory or no LVEF evaluation who proceeded to post-AC therapy. Cardiac events (congestive heart failure [CHF] or cardiac death [CD]): arm A, n = 3 (2 CHF, 1 CD); arm B, n = 19 (18 CHF, 1 CD); arm C, n = 19 (all CHF); 3-year cumulative incidence: 0.3%, 2.8%, and 3.3%, respectively. Cardiac function improved in most CHF cases following trastuzumab discontinuation and cardiac medication. Factors associated with increased risk of a cardiac event in arms B and C: older age (P < .003), prior/current antihypertensive agents (P = .005), and lower registration LVEF (P = .033). Incidence of asymptomatic LVEF decreases requiring holding trastuzumab was 8% to 10%; LVEF recovered and trastuzumab was restarted in approximately 50%. Conclusion The cumulative incidence of post-AC cardiac events at 3 years was higher in the trastuzumab-containing arms versus the control arm, but by less than 4%. Older age, lower registration LVEF, and antihypertensive medications are associated with increased risk of cardiac dysfunction in patients receiving trastuzumab following AC.
Resection of benign sciatic notch dumbbell-shaped tumors
Spinner, Robert J. , Endo, Toshiki , Amrami, Kimberly K. , Dozois, Eric J. , Babovic‐Vuksanovic, Dusica , Sim, Franklin H.

Mayo Clinic

Journal of Neurosurgery | January 24, 2008 | Volume: 105 | Issue: 6 | Pages: 873-880

10.3171/jns.2006.105.6.873 | PMID 17405258 Get It

Object The operative management of combined intrapelvic and extrapelvic sciatic notch dumbbell-shaped tumors is challenging. The relatively rare occurrence of these tumors and the varied extent of disease have made it difficult for surgeons to establish definitive surgical indications or predict favorable neurological outcomes based on preoperative imaging data. Methods In the past 3 years, the authors treated five patients presenting with radiating leg pain as a result of benign sciatic notch dumbbell-shaped tumors. These tumors in three patients with unilateral leg symptoms were considered unresectable by other neurosurgeons because of presumed direct intrinsic neural involvement. After high-resolution magnetic resonance (MR) imaging demonstrated that the extensive tumors were separate from the sciatic nerve and the lumbosacral plexus, however, these patients underwent a combined one-stage transabdominal and posterior transgluteal complete resection. Normal neurological status was maintained postoperatively in these three patients, and after more than 1 year of postoperative follow up, there were no tumor recurrences. In two patients with bilateral symptoms and extensive tumor burden, serial MR images showed that innumerable tumors directly involved the entire cross-sectional area of the sciatic nerves and extended longitudinally to the lumbosacral plexuses. Tumor debulking or resection in these patients would have resulted in neurological deficits and would not have addressed their neuropathic pain, and therefore no surgery was performed. These two patients were treated pharmacologically and advised to monitor their tumor status over the course of their lifetimes in case of malignant transformation of the tumor. Conclusions A combined one-stage transabdominal and transgluteal approach allows safe resection of selected benign but extensive sciatic notch tumors. High-resolution MR imaging is a useful tool in the management of these tumors because it allows the surgeon to visualize the anatomical relationships of the tumor to the sciatic nerve. The authors believe that as this imaging technology advances, it will provide surgeons with a method to predict definitively which sciatic notch tumors displace rather than directly involve the sciatic nerve, and therefore indicate which tumors can be resected safely and completely.
CYTOTOXIC PROPERTIES OF DIOSPYROS SEYCHELLARUM EXTRACT
Buenz, Eric J. , Bauer, Brent A. , Motley, Timothy J., Limburg, Paul J.

Mayo Clinic

The Journal of Toxicological Sciences | January 17, 2008 | Volume: 32 | Issue: 5 | Pages: 487-493

10.2131/jts.32.487 | PMID 18198480 Get It

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
Hedrick, Eric, Mass, R., Sarkar, Somnath , Suzuki, Sam, Ramanathan, Ramesh K., Hurwitz, Herbert I. , Goldberg, Richard M. , Sargent, Daniel J. , Grothey, Axel , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | January 8, 2008 | Volume: 26 | Issue: 2 | Pages: 183-189

10.1200/jco.2007.13.8099 | PMID 18182660 Get It

Purpose In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC). In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit compared with IFL. As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response. Patients and Methods For these retrospective, exploratory analyses, patients were defined as responders or nonresponders by whether complete or partial response was achieved with first-line therapy. Results Compared with IFL alone, BV plus IFL and FOLFOX each demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) regardless of objective tumor response. BV-treated nonresponders had a hazard ratio (HR) of 0.63 (P = .0001) for PFS and 0.76 (P = .0188) for OS compared with IFL-treated nonresponders. FOLFOX-treated nonresponders had an HR of 0.75 (P = .0029) for PFS and 0.74 (P = .0030) for OS compared with IFL-treated nonresponders. Conclusion In both AVF2107g and N9741, objective response did not predict the magnitude of PFS or OS benefit from the superior therapy; nonresponders, despite a poorer prognosis than responders, achieved extended PFS and OS from BV plus IFL or FOLFOX compared with IFL. On the basis of these data, tumor response in metastatic colorectal cancer is not a necessary factor for a therapy to provide benefit to an individual patient.
Mayo Clinic Risk Score for Percutaneous Coronary Intervention Predicts In-Hospital Mortality in Patients Undergoing Coronary Artery Bypass Graft Surgery
Li, Shuang , Rumsfeld, John S., Spertus, John A. , O’Brien, Sean M. , Suri, Rakesh M. , Singh, Mandeep , Gersh, Bernard J. , Peterson, Eric D. , Spertus, John A

Mayo Clinic

Circulation | January 3, 2008 | Volume: 117 | Issue: 3 | Pages: 356-362

10.1161/circulationaha.107.711523 | PMID 18172033 Get It

Background— Current risk models predict in-hospital mortality after either coronary artery bypass graft surgery or percutaneous coronary interventions separately, yet the overlap suggests that the same variables can define the risks of alternative coronary reperfusion therapies. Our goal was to seek a preprocedure risk model that can predict in-hospital mortality after either percutaneous coronary intervention or coronary artery bypass graft surgery. Methods and Results— We tested the ability of the recently validated, integer-based Mayo Clinic Risk Score (MCRS) for percutaneous coronary intervention, which is based solely on preprocedure variables (age, creatinine, ejection fraction, myocardial infarction ≤24 hours, shock, congestive heart failure, and peripheral vascular disease), to predict in-hospital mortality among 370 793 patients in the Society of Thoracic Surgeons database undergoing isolated coronary artery bypass graft surgery from 2004 to 2006. For the Society of Thoracic Surgeons coronary artery bypass graft surgery population studied, the median age was 66 years (quartiles 1 to 3, 57 to 74 years), with 37.2% of patients ≥70 years old. A high prevalence of comorbid conditions, including diabetes mellitus (37.1%), hypertension (80.5%), peripheral vascular disease (15.3%), and renal disease (creatinine ≥1.4 mg/dL; 11.8%), was present. A strong association existed between the MCRS and the observed mortality in the Society of Thoracic Surgeons database. The in-hospital mortality ranged between 0.3% (95% confidence interval 0.3% to 0.4%) with a score of 0 on the MCRS and 33.8% (95% confidence interval 27.3% to 40.3%) with an MCRS score of 20 to 24. The discriminatory ability of the MCRS was moderate, as measured by the area under the receiver operating characteristic curve (C-statistic=0.715 to 0.784 among various subgroups); performance was inferior to the Society of Thoracic Surgeons model for most categories tested. Conclusions— This model, which is based on 7 preprocedure risk variables, may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process before percutaneous or surgical revascularization.
Levorphanol Revisited
Prommer, Eric

Mayo Clinic

Journal of Palliative Medicine | December 20, 2007 | Volume: 10 | Issue: 6 | Pages: 1228-1230

10.1089/jpm.2007.0133 | PMID 18095794 Get It